Acoramidis Hydrochlorid Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 400 mg
Reference Brands: Attruby (USA), Beyonttra (EU)
Category:
Heart Disorder
Acoramidis hydrochlorid is available in Tablets
and strengths such as 400 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Acoramidis hydrochlorid is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Acoramidis hydrochlorid can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Acoramidis, marketed under the brand name Attruby, is a disease-modifying medication used for the treatment of cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM) in adults. It is a near-complete (>90%) transthyretin stabilizer, developed to mimic the protective properties of the naturally occurring T119M mutation, which helps prevent the misfolding and aggregation of transthyretin proteins. By stabilizing the transthyretin tetramer, Acoramidis reduces the formation of amyloid deposits in cardiac tissues, addressing the underlying cause of ATTR-CM rather than just managing symptoms. This mechanism helps slow the progression of the disease, improve cardiac function, and reduce the risk of cardiovascular-related hospitalizations and death in patients with wild-type or variant ATTR-CM. Administered orally in tablet form, Acoramidis provides a convenient treatment option for long-term management. Its development represents a significant advancement in targeted therapies for amyloid cardiomyopathy, offering patients a clinically proven approach to modifying disease progression. Attruby is manufactured under stringent quality standards and is approved for use in
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing